Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes.

Abstract

A new disaccharidase inhibitor, AO-128, showed 190-3900-fold more potent inhibition of purified rat small intestine sucrase-isomaltase (S-1) complex and 23-33-fold more potent inhibition of semipurified porcine small intestine disaccharidases than acarbose. AO-128 suppressed elevation of the blood glucose concentration after oral sucrose, maltose, and starch, but not after oral glucose, fructose, and lactose. The chronic addition of AO-128 to the diet produced antiobesity and antidiabetic actions in obese and/or diabetic animals. Undesirable side effects, such as diarrhea and soft feces, were observed only for the first 5-7 d and suppression of intestinal disaccharidase activities was observed even at the end of the experiment, suggesting that the suppressive or delaying effect of AO-128 on elevation of the postprandial blood glucose concentrations is involved in reduction in body weight gain and prevention and/or amelioration of the diabetic state. Thus, AO-128 is useful as an adjunct to the dietary management of obesity and diabetes.

• Authors: T Matsuo, H Odaka, H Ikeda
• Journal: The American journal of clinical nutrition (Am J Clin Nutr) Vol. 55 Issue 1 Suppl Pg. 314S-317S (01 1992) ISSN: 0002-9165 [Print] United States
• PMID: 1728846 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Cyclohexanols
• Glycoside Hydrolase Inhibitors
• Trisaccharides
• AO 128
• Disaccharidases
• Oligo-1,6-Glucosidase
• Sucrase
• Acarbose

Topics

• Acarbose
• Animals
• Cyclohexanols (pharmacology, therapeutic use)
• Diabetes Mellitus, Experimental (drug therapy)
• Disaccharidases (antagonists & inhibitors)
• Glycoside Hydrolase Inhibitors
• Intestines (enzymology)
• Male
• Obesity (drug therapy)
• Oligo-1,6-Glucosidase (antagonists & inhibitors)
• Rats
• Rats, Inbred Strains
• Rats, Zucker
• Sucrase (antagonists & inhibitors)
• Trisaccharides (pharmacology)